Literature DB >> 34406054

Hepatocellular Carcinoma Staging: Differences Between Radiologic and Pathologic Systems and Relevance to Patient Selection and Outcomes in Liver Transplantation.

Guilherme Moura Cunha1, Mojgan Hosseini2, Alessandro Furlan3, Kathryn J Fowler4.   

Abstract

Liver transplant is indicated with curative intent for patients with early-stage hepatocellular carcinoma (HCC). The radiologic T category is used to determine candidacy and priority of patients on the waiting list. After transplant, the explant liver pathologic TNM stage is used as a predictor of postoperative outcomes and overall prognosis. Although the comparison of radiologic and pathologic T categories for concordance is often considered to be straightforward, the staging conventions significantly differ. Not accounting for these differences is in part the reason for the high rates of radiologic-pathologic discordance reported in the literature, with inconsistent terminology being an additional source of confusion when evaluating concordance. These factors may affect the understanding of important radiopathologic phenotypes of disease and the adequate investigation of their prognostic capabilities. The aims of this article are to provide an overview of the pathologic and radiologic TNM staging systems for HCC while describing staging procedures, emphasize the differences between these staging systems to highlight the limitations of radiologic-pathologic stage correlation, present a review of the literature on the prognostic value of individual features used for HCC staging; and signal significant aspects of preoperative risk stratification that could be improved to positively impact posttransplant outcomes.

Entities:  

Keywords:  hepatocellular carcinoma; liver; pathology; radiology; transplantation

Mesh:

Year:  2021        PMID: 34406054     DOI: 10.2214/AJR.21.26436

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  2 in total

1.  Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.

Authors:  Maen Abdelrahim; Abdullah Esmail; Godsfavour Umoru; Kiersten Westhart; Ala Abudayyeh; Ashish Saharia; Rafik M Ghobrial
Journal:  Curr Oncol       Date:  2022-06-15       Impact factor: 3.109

2.  Safety of percutaneous, image-guided biopsy of hepatocellular carcinoma with and without concurrent ablation.

Authors:  Justin R Tse; Kevin Terashima; Luyao Shen; Justin P McWilliams; David S K Lu; Steven S Raman
Journal:  Abdom Radiol (NY)       Date:  2022-04-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.